Systemic therapy strategies for head-neck carcinomas: Current status;Systemische Therapiestrategien bei Kopf-Hals-Karzinomen

Laryngo- Rhino- Otologie

Volumn 91, Issue SUPPL. 1, 2012, Pages

  Hoffmann, T K ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

antibody; biological; chemotherapy; head neck carcinoma; medical therapy; squamous cell carcinoma of the head and neck; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; TAXANE DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; HEAD AND NECK CARCINOMA; HUMAN; LARYNX CANCER; MEDICAL DECISION MAKING; METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMIC THERAPY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84859313148     PISSN: 09358943     EISSN: 14388685     Source Type: Journal    
DOI: 10.1055/s-0031-1297244     Document Type: Article

References (212)

1. Krebs in Deutschland, Häufigkeiten und Trends Herausgeber: Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., 5. überarbeitete, aktualisierte Ausgabe Saarbrücken. 2006
2. Argiris A, Karamouzis M V, Raben D, Ferris R L. Head and neck cancer. Lancet: 2008; 371 1695 1709 (Pubitemid 351671886)
3. Lang S, Wollenberg B, Dellian M, Steuer-Vogt M K, Schwenzer K, Sautier W, Chucholowski M, Eckel R, Faas I, Wilmes E, Ehrenfeld M, Arnold W, Kastenbauer E, Hölzel D. Clinical and epidemiological data of patients with malignomas of the head and neck. Laryngorhinootologie: 2002; 81 499 508 (Pubitemid 34823775)
4. Vokes E E, Weichselbaum R R, Lippman S M, Hong W K. Head and neck cancer. N Engl J Med: 1993; 328 184 194
5. Al-Sarraf M. Chemotherapeutic management of head and neck cancer. Cancer Metast Rev: 1987; 6 191 198
6. Brownman G P, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we learned from randomized trials. Sem Oncol: 1994; 21 311 319 (Pubitemid 24191590)
7. Knox R J, Friedlos F, Lydall D A et al. Mechanism of cytotoxicity of anticancer drugs: evidence that cis-diammin-dichloroplatinum (II) and cis-diammine (1,1-cyclobutanedicarboxylato) platinum (II) differ only in their interaction with DNA. Cancer Res: 1986; 46 1972 1979 (Pubitemid 16080411)
8. Elferink F, van der Vijgh WJ F, Klein I, Vermorken J B, Gall H E, Pinedo H M. Pharmacokinetics of carboplatin after iv administration. Cancer Treat Rep: 1987; 71 1231 1237
9. Eisenberger M, Van Echo D, Aisner J. Carboplatin: the experience in head and neck cancer. Sem Oncol: 1989; 16 34 41 (Pubitemid 19138344)
10. Canetta R, Rozencweig M, Carter S K. Carboplatin: the clinical spectrum to date. Cancer Treat Rev: 1985; 12 125 136 (Pubitemid 16167909)
11. Aisner J, Sinibaldi V, Eisenberger M. Carboplatin in the treatment of squamous cell head and neck cancers. Sem Oncol: 1992; 19 60 65
12. Al-Sarraf M. Management strategies in head and neck cancer: The role of carboplatin. In: Brunns P A, Canetta R, Ozols R F. (eds.). Carboplatin: Current perspectives and future directions. Philadelphia W.B. Saunders: 1990
13. De Andres L, Brunet J, Lopez-Pousa A et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol: 1995; 13 1493 1500
14. Forastiere A A, Metch B, Schuller D E, Ensley J F, Hutchins L F, Triozzi P, Kish J A, McClure S, VonFeldt E, Williamson S K et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol: 1992; 10 1245 1251
15. Leuchtenberger C, Lewisohn R, Laslo D, Leuchtenberger R. Folic acid - a tumor growth inhibitor. Proc Soc Exp Biol Med: 1944; 55 204 205
16. Franklin A L, Belt M, Stockstad EL R, Jukes T H. Biological studies with 4-amino-10-methylpteroyl-glutamic acid. J Biol Chem: 1949; 177 621 629
17. Heidelberger C, Chandhari N K, Dannenberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer R J, Pleven E, Scheiner J. Fluorinated pyrimidines; a new class of tumor inhibitory compounds. Nature: 1957; 179 663 666
18. Sommer A, Santi D V. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2-deoxyuridylate and methylene tetrachloride. Biochem Biophys Res Commun: 1974; 57 689 696
19. Schütz J D, Collins J M, Wallace H J et al. Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. Cancer Res: 1986; 46 119 123 (Pubitemid 16189038)
20. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke K D. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol: 2005; 23 1125 1135 (Pubitemid 46202268)
21. Dreyfuss A I, Clark J R, Norris C M, Rossi R M, Lucarini J W, Busse P M, Poulin M D, Thornhill L, Costello R, Posner M R. Docetaxel: an active Drug for squamous cell carcinoma of the head and neck. J Clin Oncol: 1996; 14 1672 1678 (Pubitemid 26134226)
22. Posner M R, Hershock D M, Blajman C R, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin D M, Cullen K, Ervin T J, Murphy B A, Raez L E, Cohen R B, Spaulding M, Tishler R B, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter K W, Dugan M, Cmelak A, Markoe A M, Read P W, Steinbrenner L, Colevas A D, Norris C M Jr, Haddad R I. TAX 324 Study Group Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med: 2007; 357 1705 1715 (Pubitemid 350005152)
23. Vermorken J B, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart J S, Jelic S, Betka J, Preiss J H, van den Weyngaert D, Awada A, Cupissol D, Kienzer H R, Rey A, Desaunois I, Bernier J, Lefebvre J L. EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med: 2007; 357 1695 1704
24. Umezawa H. Bleomycin and other antitumor antibiotics of high molecular weight. Antimicrob Agents Chemother: 1985; 5 1079 1085
25. Müller WE G, Zahn R K. Bleomycin: mode of action on DNA. Gann Monogr: 1976; 19 51 62
26. Madoc-Jones H, Mauro F. Interphase action of vinblastine and vincristine: differences in their lethal action through the mitotic cycle of cultured mamalian cells. J Cell Physiol: 1968; 72 185 196
27. Cheng E, Young C W, Wittes R E. Phase II trial of vindesine in advanced head and neck cancer. Cancer Treat Rep: 1980; 64 1141 1142 (Pubitemid 11099030)
28. Smart C, Rochlin D, Nahum A, Silva A, Wagner D. Clinical experience with vinblastine sulphate in squamous cell and other malignancies. Cancer Chemoth Rep: 1964; 34 31 45
29. Dietz A, Weber A, Dollner R. Hildebrandt. Nicht resektable Kopf-Hals-Tumoren und deren Therapie. Laryngo-Rhino-Otol: 2005; 84 200 206
30. Brownman G P, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we learned from randomized trials. Sem Oncol: 1994; 21 311 319 (Pubitemid 24191590)
31. Buchdunger E, Mett H, Trinks U, Regenass U, Müller M, Meyer T, Beilstein P, Wirz B, Schneider P, Traxler P, Lyodon N B. 4,5-bis(4- fluoroanilino) phtalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cancer Res: 1995; 1 813 821
32. Holsinger F C, Kies M S, Diaz E M Jr et al. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol: 2009; 27 1976 1982
33. Divi V, Worden F P, Prince M E, Eisbruch A, Lee J S, Bradford C R, Chepeha D B, Teknos T N, Hogikyan N D, Moyer J S, Tsien C I, Urba S G, Wolf G T. Chemotherapy alone for organ preservation in advanced laryngeal cancer. Head Neck: 2010; 32 1040 1047
34. Wright J C, Cobb J B, Gumport S L, Safadi D. Investigation of the relationship between clinical and tissue-culture response to chemotherapeutic agents on human cancer. N Engl J Med: 1957; 257 1207
35. von Hoff D D, Sanbach J F, Clark G M, Turner J N, Forseth B F, Piccart M J, Colombo N, Muggia F M. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst: 1980; 82 110
36. Weisenthal L M. Predictive assays for drug and radiation resistance. In: Masters (ed.). Human cancer in primary culture. Kluver Verlag: 1991; S. 103 S. 146
37. Dietz A, Boehm A, Horn I S, Kruber P, Bechmann I, Golusinski W, Niederwieser D, Dollner R, Remmerbach T W, Wittekind C, Dietzsch S, Hildebrandt G, Wichmann G. Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol: 2010; 267 483 494
38. Dollner R, Granzow C, Neudert M, Dietz A. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res: 2006; 26 1651 1655
39. Hoffmann T K, Sonkoly E, Hauser U, van Lierop A, Whiteside T L, Klussmann J P, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K, Erjala K, Grnman R, Schipper J, Bier H, Balz V. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol: 2008; 44 1100 1109
40. Ensley J F, Jacos J R, Weaver A et al. Correlation between response to cisplatinum-combination therapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer: 1984; 54 811 814 (Pubitemid 14058432)
41. Urba S G, Wolf G T, Eisbruch A et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol: 2006; 24 593 598 (Pubitemid 46630421)
42. Relic A, Scheich M, Stapf J, Voelter C, Hoppe F, Hagen R, Pfreundner L. Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas. Eur Arch Otorhinolaryngol: 2009; 266 1799 1805
43. Kumar B, Cordell K G, Lee J S, Worden F P, Prince M E, Tran H H, Wolf G T, Urba S G, Chepeha D B, Teknos T N, Eisbruch A, Tsien C I, Taylor J M, D'Silva N J, Yang K, Kurnit D M, Bauer J A, Bradford C R, Carey T E. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol: 2008; 26 3128 3137
44. Worden F P, Kumar B, Lee J S, Wolf G T, Cordell K G, Taylor J M, Urba S G, Eisbruch A, Teknos T N, Chepeha D B, Prince M E, Tsien C I, D'Silva N J, Yang K, Kurnit D M, Mason H L, Miller T H, Wallace N E, Bradford C R, Carey T E. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol: 2008; 26 3138 3146
45. Worden F P, Moyer J, Lee J S, Taylor J M, Urba S G, Eisbruch A, Teknos T N, Chepeha D B, Prince M E, Hogikyan N, Lassig A A, Emerick K, Mukherji S, Hadjiski L, Tsien C I, Miller T H, Wallace N E, Mason H L, Bradford C R, Wolf G T. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope: 2009; 119 1510 1517
46. Ganzer U, Bier H, Bachert C. Kritische Anmerkungen zur Chemotherapie bösartiger Kopf- und Halsgeschwülste. Laryng Rhinol Otol: 1987; 66 200 204 (Pubitemid 17115666)
47. Knecht R. Strahlen-, Chemo- und Targettherapie von Kopf-Hals-Karzinomen. HNO: 2009; 57 436 445
48. Weaver A, Flemming S, Kish J, Vandenberg H, Jacob J, Crissman J, Al-Sarraf M. Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer. Am J Surg: 1982; 144 445 448 (Pubitemid 12037517)
49. Weaver A, Fleming S, Ensley J, Kish J A, Jacobs J, Kinzie J, Crissman J, Al-Sarraf M. Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg: 1984; 148 525 529 (Pubitemid 14012949)
50. Wittes R, Heller K, Randolph V, Howard J, Vallejo A, Farr H, Harrold C, Gerold F, Shah J, Spiro R, Strong E. Cis-Dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep: 1979; 63 1533 1538 (Pubitemid 10167751)
51. Clark J R, Frei E. Chemotherapy for head and neck cancer: progress and controversy in management of patients with Mo disease. Sem Oncol: 1989; 16 44 57 (Pubitemid 19215262)
52. The Department of Veterans Affairs Laryngeal Cancer Study Group Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The VA Laryngeal Cancer Study Group. N Engl J Med: 1991; 324 1685 1690
53. Lefebvre J L, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst: 1996; 88 890 899 (Pubitemid 26230640)
54. Pignon J P, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet: 2000; 355 949 955 (Pubitemid 30148259)
55. Domenge C, Hill C, Lefebvre J L, De Raucourt D, Rhein B, Wibault P, Marandas P, Coche-Dequeant B, Stromboni-Luboinski M, Sancho-Garnier H, Luboinski B. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer: 2000; 83 1594 1598 (Pubitemid 32001699)
56. Paccagnella A, Orlando A, Marchiori C, Zorat P L, Cavaniglia G, Sileni V C, Jirillo A, Tomio L, Fila G, Fede A et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst: 1994; 86 265 272 (Pubitemid 24057404)
57. Zorat P L, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione C A, Boldrin F, Marchiori C, Lunghi F, Fede A, Bordin A, Da Mosto M C, Sileni V C, Orlando A, Jirillo A, Tomio L, Pappagallo G L, Ghi M G. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst: 2004; 96 1714 1717 (Pubitemid 39591589)
58. Pignon J P, le Matre A, Maillard E, Bourhis J. MACH-NC Collaborative Group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17 346 patients. Radiother Oncol: 2009; 92 4 14
59. Program HaNC Adjuvant chemotherapy for advanced head and neck squamous cell carcinoma: Final report of Head and Neck Contracts Program. Cancer: 1987; 60 301 311
60. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol: 2005; 23 8636 8645 (Pubitemid 46211506)
61. Lorch J H, Goloubeva O, Haddad R I, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino D E, Posner M R. TAX 324 Study Group Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol: 2011; 12 153 159
62. Parthan A, Posner M R, Brammer C, Beltran P, Jansen J P. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck: 2009; 31 1255 1262
63. Paccagnella A, Ghi M G, Loreggian L, Buffoli A, Koussis H, Mione C A, Bonetti A, Campostrini F, Gardani G, Ardizzoia A, Dondi D, Guaraldi M, Cavallo R, Tomio L, Gava A. Gruppo di Studio Tumori della Testa e del Collo XRP 6976 F/2501 Study Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol: 2010; 21 1515 1522
64. Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schroder U, Eckel H, Hess M, Schroder M, Schneider P, Jens B, Zenner H P, Werner J A, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOSI-trial). Eur Arch Otorhinolaryngol: 2009; 266 1291 1300
65. Knecht R, Baghi M, Hambek M, Zamboglou N, Tesch H. TPF induction chemotherapy followed by concurrent radiochemotherapy in the first line therapy of advanced carcinomas of the larynx and pharynx (phase IIb trial). J Clin Oncol: 2006; 24 Abstract 5562
66. Atassi B, Ozgursoy O, Yoo G H, Jacobs J R, Bhatti N S, Mal M, Kim H, Lin H, Sukari A. Influence of induction chemotherapy on patients' compliance to radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. J Clin Oncol: 2011; 29 abstr 5558
67. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst: 2009; 101 498 506
68. Semrau S, Waldfahrer F, Lell M, Linke R, Klautke G, Kuwert T, Uder M, Iro H, Fietkau R. Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results. Strahlenther Onkol: 2011; 187 15 22
69. Peres J. HPV-positive oropharyngeal cancer: data may justify new approach. J Natl Cancer Inst: 2010; 102 1456 1459
70. Posner M R. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist: 2005; 10 11 19 (Pubitemid 43152726)
71. Schneider I, Holzgraefe M, Schröder M. Carboplatin and paclitaxel induction chemotherapy for patients with oropharynx carcinoma. Laryngorhinootologie: 2008; 87 719 722
72. Driemel O, Ettl T, Kölbl O, Reichert T E, Dresp B V, Reuther J, Pistner H. Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy. Strahlenther Onkol: 2009; 185 296 302
73. Eich H T, Löschcke M, Scheer M, Kocher M, Bongartz R, Wacker S, Zöller J E, Müller R P. Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity. Outcome of 134 patients. Strahlenther Onkol: 2008; 184 23 29
74. Keßler P, Grabenbauer G, Leher A et al. 5- Jahresüberlebenswahrscheinlichkeit von Patienten mit primären Plattenepithelkarzinomen der Mundhöhle. Vergleich von zwei Behandlungsstrategien in einer prospektiven Studie. Strahlenther Onkol: 2007; 4 184 189 (Pubitemid 46570755)
75. Mohr C, Bohndorf W, Carstens J et al. Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone. A prospective, multicentric randomized DSAK study of advanced squamous cell carcinoma of the oral cavity and the oropharynx (a 3-year follow-up). Int J Oral Maxillofac Surg: 1994; 23 140 148
76. Vokes E E, Weichselbaum R R. Concomitant chemotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol: 1990; 8 911 934 (Pubitemid 20148286)
77. Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol: 1997; 43 29 37 (Pubitemid 27191976)
78. Munro A J. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer: 1995; 71 83 91
79. Brizel D M, Albers M E, Fisher S R, Scher R L, Richtsmeier W J, Hars V, George S L, Huang A T, Prosnitz L R. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med: 1998; 338 1798 1804 (Pubitemid 28277960)
80. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst: 1999; 91 2081 2086 (Pubitemid 30019568)
81. Dobrowsky W, Naud J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol: 2000; 57 119 124
82. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol: 2000; 18 1458 1464 (Pubitemid 30205391)
83. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel H E, Mueller R P. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys: 2001; 50 1161 1171 (Pubitemid 32727792)
84. Forastiere A A, Goepfert H, Maor M, Pajak T F, Weber R, Morrison W, Glisson B, Trotti A, Ridge J A, Chao C, Peters G, Lee D J, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med: 2003; 349 2091 2098 (Pubitemid 37464533)
85. Forastiere A A, Maor M, Weber R et al. Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynxinduction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc Am Soc Clin Oncol: 2006; 24 284s
86. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Calais G. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys: 2003; 55 93 98 (Pubitemid 36020347)
87. List M A, Siston A, Haraf D, Schumm P, Kies M, Stenson K, Vokes E E. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol: 1999; 17 1020 1028 (Pubitemid 29109336)
88. Rosenthal D I, Lewin J S, Eisbruch A. Dysphagia after radiation therapy or chemoradiation for head and neck cancer. J Clin Oncol: 2006; 24 2636 2643 (Pubitemid 46622085)
89. Rudat V, Eckel H, Volling P, Schröder M, Staar S, Wallner F, Wannenmacher M, Dietz A. Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with carboplatin. Radiother Oncol: 2008; 89 33 37
90. American Society of Clinical Oncology Pfister D G, Laurie S A, Weinstein G S, Mendenhall W M, Adelstein D J, Ang K K, Clayman G L, Fisher S G, Forastiere A A, Harrison L B, Lefebvre J L, Leupold N, List M A, O'Malley B O, Patel S, Posner M R, Schwartz M A, Wolf G T. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol: 2006; 24 3693 3704 (Pubitemid 46630546)
91. Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol: 2004; 22 19 22 (Pubitemid 41095109)
92. Lefebvre J L, Ang K K, Ang K, Bardet E, Barry B, Bernier J, Bourhis J, Budach V, Calais G, Conley B, Forastiere A, Knecht R, Langendijk J, Lefebvre J L, Leemans R, Licitra L, Posner M, de Raucourt D, Rolland F, Temam S, Vermorken J B, Vokes E, Weber R S, Wolf G. Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Head Neck: 2009; 31 429 441
93. Lefebvre J L, Ang K K. Larynx Preservation Consensus Panel Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Int J Radiat Oncol Biol Phys: 2009; 73 1293 1303
94. Wang C J, Knecht R. Current concepts of organ preservation in head and neck cancer. Eur Arch Otorhinolaryngol: 2011; 268 481 487
95. Armand J P, Couteau C. Chemotherapy in head and neck cancer. Eur J Cancer: 1995; 31 819 822
96. Forastiere A A. Randomized trials of induction chemotherapy: a critical review. Hematol Oncol Clin North Am: 1991; 5 725 736
97. Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the head and neck contracts program. J Clin Oncol: 1990; 8 838 847 (Pubitemid 20148276)
98. Laramore G E, Scott C B, al Sarraf M, Haselow R E, Ervin T J, Wheeler R, Jacobs J R, Schuller D E, Gahbauer R A, Schwade J G. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on intergroup study 0034. Int J Radiat Oncol Biol Phys: 1992; 23 705 713
99. Schuller D E, Metch B, Stein D W, Mattox D, McCracken J D. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the southwest oncology group. Laryngoscope: 1988; 98 1205 1211
100. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med: 2004; 350 1945 1952 (Pubitemid 38580197)
101. Cooper J S, Pajak T F, Forastiere A A, Jacobs J, Campbell B H, Saxman S B, Kish J A, Kim H E, Cmelak A J, Rotman M, Machtay M, Ensley J F, Chao K S, Schultz C J, Lee N, Fu K K. Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med: 2004; 350 1937 1944
102. Bernier J, Cooper J S, Pajak T F, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin E M, Jacobs J R, Jassem J, Ang K K, Lefbvre J L. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck: 2005; 27 843 850 (Pubitemid 41395696)
103. Vokes E E. Head and neck cancer. In: Perry M C. (ed.). Chemotherapy Source Book. Baltimore Williams & Wilkins: 1992; 918 931
104. Armand J P, Cvitkovik E, Recondo G. Salvage chemotherapy in recurrent head and neck cancer: The Institut Gustave Roussy Experience. Am J Oncol: 1993; 14 301 306 (Pubitemid 23275052)
105. Colevas A D. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol: 2006; 24 2644 2652 (Pubitemid 46628471)
106. Clavel M, Vermorken J B, Cognetti F, Cappelaere P, de Mulder P H, Schornagel J H, Tueni E A, Verweij J, Wildiers J, Clerico M et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol: 1994; 5 521 526 (Pubitemid 24223504)
107. Gibson M K, Li Y, Murphy B et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol: 2005; 23 3562 3567
108. Benasso M, Ponzanelli A, Merlano M, Numico G, Ricci I, Vigo V, Grossi F, Amadori D, Cavallo G, Capaccetti B, Taveggia P, Boni L, Rosso R. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. Acta Oncol: 2006; 45 168 174
109. Vermorken J B, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H R, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med: 2008; 359 1116 1127
110. Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technol Assess: 2009; 13 49 54
111. Len X, Hitt R, Constenla M, Rocca A, Stupp R, Kovcs A F, Amellal N, Bessa E H, Bourhis J. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol): 2005; 17 418 424 (Pubitemid 41136136)
112. Martinez-Trufero J, Isla D, Adansa J C, Irigoyen A, Hitt R, Gil-Arnaiz I, Lambea J, Lecumberri M J, Cruz J J. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer: 2010; 102 1687 1691
113. Rubin Grandis J, Melhem M F, Gooding W E, Day R, Holst V A, Wagener M M, Drenning S D, Tweardy D J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst: 1998; 90 824 832 (Pubitemid 28280548)
114. Bier H, Hoffmann T, Hauser U, Wink M, Ochler M, Kovar A, Müser M, Knecht R. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol: 2001; 47 519 524 (Pubitemid 32477299)
115. Bier H, Hoffmann T, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother: 1998; 46 167 173 (Pubitemid 28239882)
116. Hoffmann T, Hafner D, Ball H, Haas I, Bier H. Antitumor activity of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma (HNSCC) lines. Anticancer Res: 1997; 17 4419 4426
117. Hoffmann T K, Schirlau K, Sonkoly E, Brandau S, Lang S, Pivarcsi A, Balz V, Muller A, Homey B, Boelke E, Reichert T, Friebe-Hoffmann U, Greve J, Schuler P, Scheckenbach K, Schipper J, Bas M, Whiteside T L, Bier H. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer: 2009; 124 2589 2596
118. Bonner J A, Harari P M, Giralt J, Azarnia N, Shin D M, Cohen R B, Jones C U, Sur R, Raben D, Jassem J, Ove R, Kies M S, Baselga J, Youssoufian H, Amellal N, Rowinsky E K, Ang K K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med: 2006; 354 567 578 (Pubitemid 43209104)
119. Bonner J A, Harari P M, Giralt J, Cohen R B, Jones C U, Sur R K, Raben D, Baselga J, Spencer S A, Zhu J, Youssoufian H, Rowinsky E K, Ang K K. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol: 2010; 11 21 28
120. Burtness B, Goldwasser M A, Flood W, Mattar B, Forastiere A A. Eastern Cooperative Oncology Group Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol: 2005; 23 8646 8654 (Pubitemid 46211507)
121. Mesa R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord J P, Bokemeyer C, Curran D, Gross A, Vermorken J B. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol: 2010; 21 1967 1973
122. Licitra L, Mesia R, Rivera F, Remenr E, Hitt R, Erfn J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken J B. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol: 2011; 22 1078 1087
123. Vermorken J B, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler M, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol: 2007; 25 2171 2177 (Pubitemid 46954639)
124. Machiels J P, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, Srensen P, Nielsen T, Lisby S, Clement P M. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol: 2011; 12 333 343
125. Ang K K, Zhang Q E, Rosenthal D I, Nguyen-Tan P, Sherman E J, Weber R S, Galvin J M, Schwartz D L, El-Naggar A K, Gillison M L, Jordan R, List M A, Konski A A, Thorstad W L, Trotti A, Beitler J J, Garden A S, Spanos W J, Yom S S, Axelrod R S. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol: 2011; 29 abstr 5500
126. Argiris A, Heron D E, Smith R P, Kim S, Gibson M K, Lai S Y, Branstetter B F, Posluszny D M, Wang L, Seethala R R, Dacic S, Gooding W, Grandis J R, Johnson J T, Ferris R L. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol: 2010; 28 5294 5300
127. Hoffmann T K, Bier H, Whiteside T L. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother: 2004; 53 1055 1067 (Pubitemid 39506395)
128. Whiteside T L. Immune responses to malignancies. J Allergy Clin Immunol: 2010; 125 S272 S283
129. Ang K K, Harris J, Wheeler R, Weber R, Rosenthal D I, Nguyen-Tn P F, Westra W H, Chung C H, Jordan R C, Lu C, Kim H, Axelrod R, Silverman C C, Redmond K P, Gillison M L. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med: 2010; 363 24 35
130. Hoffmann T K, Arsov C, Schirlau K, Bas M, Friebe-Hoffmann U, Klussmann J P, Scheckenbach K, Balz V, Bier H, Whiteside T L. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer: 2006; 118 1984 1991
131. Wansom D, Light E, Worden F, Prince M, Urba S, Chepeha D B, Cordell K, Eisbruch A, Taylor J, D'Silva N, Moyer J, Bradford C R, Kurnit D, Kumar B, Carey T E, Wolf G T. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg: 2010; 136 1267 1273
132. Wittekindt C, Wagner S, Klußmann J P. HPV-associated head and neck cancer: The basics of molecular and translational research. HNO: 2011; Epub ahead of print
133. Munger K, Howley P M. Human papillomavirus immortalization and transformation functions. Virus Res: 2002; 89 213 228 (Pubitemid 35351540)
134. Agrawal Y, Koch W M, Xiao W, Westra W H, Trivett A L, Symer D E et al. Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res: 2008; 14 7143 7150
135. Klussmann J P, Preuss S F, Speel E J. Human papillomavirus and cancer of the oropharynx. Molecular interaction and clinical implications. HNO: 2009; 57 113 122
136. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol: 2006; 24 5630 5636 (Pubitemid 46631302)
137. Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside T L, Ferrone S, DeLeo A, Ferris R L. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res: 2005; 65 11146 11155 (Pubitemid 41713386)
138. Albers A E, Hoffmann T K, Klussmann J P, Kaufmann A M. Prophylactic and therapeutic vaccines against human papilloma virus. HNO: 2010; 58 778 790
139. Seiwert T Y, Haraf D J, Cohen E E, Stenson K, Witt M E, Dekker A, Kocherginsky M, Weichselbaum R R, Chen H X, Vokes E E. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol: 2008; 26 1732 1741
140. Cohen E E, Sharma M R, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming G F, Stadler W M, Ratain M J. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer: 2011; 47 1484 1489
141. Amiel J L, Sancho-Garnier H, Vanderbrouck C et al. First results of a randomized trial on immunotherapy of head and neck tumors. Recent Results Cancer Res: 1979; 68 318 323 (Pubitemid 9194478)
142. Bier J, Rapp H J, Borsos T. Randomized study on intratumoral BCG-cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck. Immunotherapy: 1981; 12 71 75
143. Cheng V S, Suit H D, Wang C C et al. Clinical trial of Corynebacterium parvum (intra-lymph-node and intravenous) and radiation therapy in the treatment of head and neck carcinoma. Cancer: 1982; 49 239 244 (Pubitemid 12211837)
144. Donaldson R C. Chemoimmunotherapy for cancer of the head and neck. Am J Surg: 1973; 126 507 512
145. Richman S P, Livingston R B, Gutterman J U, Suen J Y, Hersh E M. Chemotherapy versus chemo-immunotherapy of head and neck cancer: report of a randomized study. Cancer Treatment Rep: 1976; 60 535 539
146. Taylor S G, Raynor WJ J, Bytell D E, Sisson G A. A randomized trial of adjuvant BCG immunotherapy in head and neck cancer. Arch Otolaryngol: 1983; 109 544 549 (Pubitemid 13030910)
147. Wanebo H J, Oettgen H F, Mike V, Pinsky C M, Strong E W, Hilal E Y. Adjuvant trial of levamisole in patients with squamous cell cancer of the head and neck: a preliminary report. Recent Results Cancer Res: 1978; 68 324 333
148. Olivari A J, Pradier R, Califano L, Guardo A, Glait H M. Levamisole in squamous cell carcinoma of the head and neck. Cancer Treatment Rep: 1979; 63 983 990 (Pubitemid 10220089)
149. Kitahara S, Ikeda M, Inouye T et al. Inhibition of head and neck metastasis and/or recurrent cancer by local administration of multi-cytokine inducer OK-432. J Laryngol Otol: 1996; 110 449 453
150. Whiteside T L. Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep: 2001; 3 46 55
151. Victora G D, Socorro-Silva A, Volsi E C, Abdallah K, Lima F D, Smith R B, Moyses R A, Zrate-Blads C R, Michaluart P, Silva C L, Kalil J, Coelho V. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther: 2009; 16 598 608
152. Wu A, Zeng Q, Kang T H, Peng S, Roosinovich E, Pai S I, Hung C F. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther: 2011; 18 304 312
153. Ferris R L, DeLeo A B, Whiteside T L. Adjuvant p53 peptide loaded DC-based therapy of subjects with squamous cell cancer of the head and neck (A phase I safety and immunogenicity trial). UPCI Protocol Pittsburgh, PA: 2003
154. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, Helmke B H, Weidauer H, Schirrmacher V, Herold-Mende C. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res: 2004; 64 8057 8061 (Pubitemid 39446943)
155. Cortesina G, De Stefani A, Galeazzi E et al. Interleukin-2 injected around tumor draining lymph nodes in head and neck cancer. Head Neck: 1991; 13 125 131
156. Mattijssen V, De Mulder P H, Schornagel J H et al. Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. J Immunother: 1991; 10 63 68
157. Vlock D R, Snyderman C H, Johnson J T et al. Phase Ib trial of the effect of peritumoral and intronodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother: 1994; 15 134 139 (Pubitemid 24047546)
158. Ikic D, Padovan I, Brodarec I, Knezevic M, Soos E. Application of human leucocyte interferon in patients with tumours of the head and neck. Lancet: 1981; 1 1025 1027 (Pubitemid 11096625)
159. Medenica R, Slack N. Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. Cancer Drug Deliv: 1985; 2 53 76 (Pubitemid 15017505)
160. Vlock D R, Johnson J, Myers E et al. Preliminary trial of non-recombinant interferon-alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck: 1991; 13 15 21
161. Agarwala S, Vlock D, Johnson J T et al. Phase II trial of interferon-alpha in locally recurrent or metastatic head and neck cancer: results of ECOG trial P-Z386. Proc Am Soc Clin Oncol: 1991; 10 205
162. Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, Willenberg H S, Schinner S, Cohnen M, Seissler J, Zacharowski K, Scherbaum W A, Schott M. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol: 2008; 180 1462 1470
163. Richtsmeier W J, Koch W M, McGuire W P, Poole M E, Chang E H. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg: 1990; 116 1271 1277 (Pubitemid 20362054)
164. Barrera J L, Verastegui E, Meneses A, Zinser J, delaGarza J, Hadden J W. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg: 2000; 126 345 351 (Pubitemid 30140389)
165. Hadden J W, Verastegui E, Hadden E. IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans. Ann N Y Acad Sci: 2007; 1112 245 255 (Pubitemid 47598670)
166. Meneses A, Verastegui E, Barrera J L, de la Garza J, Hadden J W. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. Int Immunopharmacol: 2003; 3 1083 1091 (Pubitemid 36830853)
167. Ishikawa T, Ikawa T, Eura M, Fukiage T, Masuyama K. Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumor cells and recombinant interleukin-2. Acta Otolaryngol: 1989; 107 346 351 (Pubitemid 19161089)
168. Kubota E, Katano M, Kurokawa H et al. Tumoricidal effect of human PBMC following stimulation with OK-432 and its application for locoregional immunotherapy in head and neck cancer patients. J Craniomaxillofac Surg: 1993; 21 30 37 (Pubitemid 23075536)
169. Squadrelli-Saraceno M, Rivoltini L, Cantu G, Ravagnani F, Parmiani G, Molinari R. Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori: 1990; 76 566 571
170. Sauter A, Kloft C, Gronau S, Bogeschdorfer F, Erhardt T, Golze W, Schroen C, Staab A, Riechelmann H, Hoermann K. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol: 2007; 30 927 935
171. Colnot D R, Quak J J, Roos J C, de Bree R, Wilhelm A J, Snow G B, van Dongen G A. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience. Head Neck: 2001; 23 559 565 (Pubitemid 32565529)
172. Stroomer J W, Roos J C, Sproll M et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res: 2000; 6 3046 3055 (Pubitemid 30637727)
173. To W C, Wood B G, Krauss J C et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg: 2000; 126 1225 1231
174. Cohen E E, Davis D W, Karrison T G, Seiwert T Y, Wong S J, Nattam S, Kozloff M F, Clark J I, Yan D H, Liu W, Pierce C, Dancey J E, Stenson K, Blair E, Dekker A, Vokes E E. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol: 2009; 10 247 257
175. Argiris A, Karamouzis M V, Gooding W E, Branstetter B F, Zhong S, Raez L E, Savvides P, Romkes M. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol: 2011; 29 1140 1145
176. Raguse J D, Gath H J, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol: 2004; 40 228 230 (Pubitemid 38030369)
177. Vermorken J B, Guigay J, Mesia R, Trigo J M, Keilholz U, Kerber A, Bethe U, Picard M, Brummendorf T H. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer: 2011; 104 1691 1696
178. Choong N W, Kozloff M, Taber D, Hu H S, Wade J 3rd, Ivy P, Karrison T G, Dekker A, Vokes E E, Cohen E E. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs: 2010; 28 677 683
179. Machiels J P, Henry S, Zanetta S, Kaminsky M C, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies A F, Faivre S, Moxhon A, Duprez T, Guigay J. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol: 2010; 28 21 28
180. Rischin D, Peters L J, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol: 2010; 28 2989 2995
181. Sok J C, Coppelli F M, Thomas S M, Lango M N, Xi S, Hunt J L, Freilino M L, Graner M W, Wikstrand C J, Bigner D D, Gooding W E, Furnari F B, Grandis J R. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res: 2006; 12 5064 5073 (Pubitemid 44453332)
182. Cohen E E, Kane M A, List M A, Brockstein B E, Mehrotra B, Huo D, Mauer A M, Pierce C, Dekker A, Vokes E E. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res: 2005; 11 8418 8424 (Pubitemid 41746956)
183. Kirby A M, A'Hern R P, D'Ambrosio C, Tanay M, Syrigos K N, Rogers S J et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer: 2006; 94 631 636 (Pubitemid 43361892)
184. Stewart J S, Cohen E E, Licitra L, Van Herpen C M, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin A M, Hirsch F R, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes E E. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol: 2009; 27 1864 1871
185. Siu L L, Soulieres D, Chen E X, Pond G R, Chin S F, Francis P et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol: 2007; 25 2178 2183 (Pubitemid 46954640)
186. Soulieres D, Senzer N N, Vokes E E, Hidalgo M, Agarwala S S, Siu L L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol: 2004; 22 77 85 (Pubitemid 41095117)
187. Abidoye O O, Cohen E E, Wong S J, Kozloff M F, Nattam S R, Stenson K M, Blair E A, Day S, Dancey D E, Vokes E El. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol: 2006; 24 18S 5568 (Abstract)
188. Williamson S K, Moon J, Huang C H, Guaglianone P P, LeBlanc M, Wolf G T, Urba S G. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol: 2010; 28 3330 3335
189. Fry D W, Kraker A J, McMichael A, Ambroso L A, Nelson J M, Leopold W R, Conners R W, Bridges A J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science: 1994; 265 1093 1095 (Pubitemid 24293076)
190. Buchdunger E, Mett H, Trinks U, Regenass U, Müller M, Meyer T, Beilstein P, Wirz B, Schneider P, Traxler P, Lyodon N B. 4,5-bis(4- fluoroanilino) phtalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin Cancer Res: 1995; 1 813 821
191. Yap T A, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono J S, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol: 2010; 28 3965 3972
192. Seiwert T Y, Clement P M, Cupissol D, Del Campo J, de Mont-Serrat H, Thurm H C, Blackman H S, Cohen E E. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. J Clin Oncol: 2010; 28 15 Abstract 5501
193. Hainsworth J D, Spigel D R, Burris H A 3rd, Markus T M, Shipley D, Kuzur M, Lunin S, Greco F A. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer: 2009; 115 2138 2146
194. Carducci M A, Musib L, Kies M S, Pili R, Truong M, Brahmer J R, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton D E, Herbst R S. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol: 2006; 24 4092 4099 (Pubitemid 46622284)
195. Dudek A Z, Lesniewski-Kmak K, Shehadeh N J, Pandey O N, Franklin M, Kratzke R A, Greeno E W, Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer: 2009; 100 1379 1384
196. Gleich L L, Gluckman J L, Armstrong S, Biddinger P W, Miller M A, Balakrishnan K, Wilson K M, Saavedra H I, Stambrook P J. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg: 1998; 124 1097 1104 (Pubitemid 28471598)
197. Lai S Y, Koppikar P, Thomas S M, Childs E E, Egloff A M, Seethala R R, Branstetter B F, Gooding W E, Muthukrishnan A, Mountz J M, Lui V W, Shin D M, Agarwala S S, Johnson R, Couture L A, Myers E N, Johnson J T, Mills G, Argiris A, Grandis J R. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol: 2009; 27 1235 1242
198. Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res: 2003; 63 1188 1191 (Pubitemid 36348693)
199. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, Weidauer H, Bosch F X. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene: 1998; 16 1671 1679 (Pubitemid 28175048)
200. Liu T J, Zhang W W, Taylor D L, Roth J A, Goepfert H, Clayman G L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res: 1994; 54 3662 3667 (Pubitemid 24241174)
201. Clayman G L, el-Naggar A K, Lippman S M, Henderson Y C, Frederick M, Merritt J A, Zumstein L A, Timmons T M, Liu T J, Ginsberg L, Roth J A, Hong W K, Bruso P, Goepfert H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol: 1998; 16 2221 2232 (Pubitemid 28265061)
202. Nemunaitis J J. Efficacy of adenoviral p53 gene therapy (advexin) in pivotal clinical trials for recurrent squamous cell carcinoma of the head and neck. Meeting Abstract ASGT 2008
203. Yoo G H, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg: 2009; 135 869 874
204. Nemunaitis J. A phase 3, MULTI-center, open-LABEL, randomized study of Adenoviral p53 Gene Therapy (ADVEXIN(R)) versus methotrexate in patients with recurrent, refractory squamous cell carcinoma of the head and neck (SCCHN) investigated the clinical benefit of ADVEXIN vs methotrexate to address an unmet medical need. Oral presentation, Industrial Liaison: Late Stage Industry Sponsored Clinical Trials. The American Society for Gene Therapy (ASGT) Annual Meeting Boston, MA, USA: 2009
205. Nemunaitis J, Clayman G, Agarwala S S, Hrushesky W, Wells J R, Moore C, Hamm J, Yoo G, Baselga J, Murphy B A, Menander K A, Licato L L, Chada S, Gibbons R D, Olivier M, Hainaut P, Roth J A, Sobol R E, Goodwin W J. Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res: 2009; 15 7719 7725
206. Khuri F R, Nemunaitis J, Ganly I, Arseneau J, Tannock I F, Romel L, Gore M, Ironside J, MacDougall R H, Heise C, Randlev B, Gillenwater A M, Bruso P, Kaye S B, Hong W K, Kirn D H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med: 2000; 6 879 885 (Pubitemid 30644745)
207. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res: 2000; 60 6359 6366
208. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol: 2001; 19 289 298 (Pubitemid 32112839)
209. Nemunaitis J, Cunningham C, Tong A W, Post L, Netto G, Paulson A S, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther: 2003; 10 341 352 (Pubitemid 36528778)
210. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther: 2005; 16 1016 1027 (Pubitemid 41324561)
211. Wollenberg B. Implication of stem cells in the biology and therapy of head and neck cancer. Laryngorhinootologie: 2011; 90 S110 S119
212. Mozet C, Wichmann G, Dietz A. Translational approaches in cancer stem cell research. HNO: 2011; Aug 18. Epub ahead of print